IL-35 (human):Fc (human), (recombinant)



ALX-522-140-C010	10 µg	360.00 USD

EBI3 (Epstein-Barr virus-induced gene 3 protein; EBV-induced gene 3 protein; IL-27B; IL-27 subunit β) and IL-12A (IL-12 subunit p35; CLMF p35) form the heterodimeric cytokine IL-35 (interleukin-35) involved in T cell regulation. IL-35 is highly expressed in regulatory T cell (Treg) but not in effector or naive T cells. IL-35 is required for the suppressive function of T-reg in vitro and in vivo.

Product Specification

Alternative Name:	Interleukin-35, EBI3:IL-12A, IL-27B:CLMF p35

Concentration:	0.1mg/ml after reconstitution.

Endotoxin Content:	<0.1EU/µg purified protein (LAL test; Lonza).

MW:	~85kDa

Purity:	≥95% (SDS-PAGE)

Formulation:	Lyophilized. Contains PBS.

Activity:	IL-35 binds to IL-12Rß2, and has been demonstrated in the literature to inhibit mononuclear cell proliferation

Biological Activity:	Inhibits human mononuclear cell proliferation.

Source/Host:	Produced in HEK 293 cells. Human EBI3 (aa 21-229) linked to human IL-12A (aa 23-219) via the linker GGGSGGGSGGGSGGGS is fused at the C-terminus to the Fc portion of human IgG1 and a FLAG^®-tag.

Reconstitution:	Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein.

Short Term Storage:	+4°C

Long Term Storage:	-20°C

Use/Stability:	Stable for at least 6 months after receipt when stored at -20°C.

Handling:	After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.

Background / Technical Information:	UniProt ID Q14213: IL-27B (human) UniProt ID P29459: IL-12A (human) FLAG is a registered trademark of Sigma-Aldrich Co.

Product Literature References

Regulatory T-Cell (Treg) hybridoma as a novel tool to study Foxp3 regulation and Treg fate: R. Sharma, et al.; J. Autoimmun. 37, 113 (2011), Abstract;

Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC: M. Seyerl, et al.; Eur. J. Immunol. 40, 321 (2010), Abstract;

General Literature References

IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells: W. Niedbala, et al.; Eur. J. Immunol. 37, 3021 (2007), Abstract; Full Text

The inhibitory cytokine IL-35 contributes to regulatory T-cell function: L.W. Collison, et al. ; Nature 450, 566 (2007), Abstract;

Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin: O. Devergne, et al.; PNAS 94, 12041 (1997), Abstract; Full Text